Cat. No.: HY-123115

Leucrose

(Synonyms: 5-O-α-D-Glucopyranosyl-D-fructose)

Customer Review

Based on 1 Customer Validation

Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.

For research use only. We do not sell to patients.

Purity: 98.53%
CAS No.: 7158-70-5
Formula: C₁₂H₂₂O₁₁
Molecular Weight:342.30

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Leucrose Chemical Structure

CAS No.: 7158-70-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

JAK1

STAT6

IL-1β

All JAK Isoforms :

All STAT Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

In Vitro

Leucrose (24 h) does not alter RAW 264.7 macrophage cell viability relative to glucose treatment in DMEM containing IL4 (20 ng/mL) and total glucose
content (25 mM) partially substituted with leucrose, but upregulates M2 macrophage markers (CD163, Arg1) and increases JAK1/STAT6 phosphorylation^[1].
Leucrose is hydrolyzed into
glucose and fructose by α-glucosidase in the small intestine and suppresses adipogenesis and down-regulates adipogenesis-related gene expression in 3T3-L1 adipocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

RAW 264.7 macrophage cells
Concentration:

25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
Incubation Time:

24 h
Result:

Significantly exceeds levels in the non-treated control group across all treated groups.
Shows no significant difference between leucrose-treated groups (25% and 50% substitution) and the glucose-treated group.

Western Blot Analysis^[1]

Cell Line:

RAW 264.7 macrophage cells
Concentration:

25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
Incubation Time:

24 h (with 20 ng/mL IL-4)
Result:

Increases CD163 levels by 99.0% in the 50% leucrose substitution group compared to the high-glucose control group.
Increases Arg1 levels by 78.6% in the 50% leucrose substitution group compared to the high-glucose control group.
Significantly increases p-JAK1 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
Significantly increases p-STAT6 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.

In Vivo

Leucrose (25-50% of total sucrose content replaced; p.o.; ad libitum in diet; continuously for 5 weeks) supplementation suppresses DSS (HY-116282C)-induced colitis in C57BL/6 mice, with the 50% replacement group reducing DAI AUC_0-t by 37.3%, restoring colon length by 20.3%, and reducing colon tissue IL-1β mRNA levels by 81.1% relative to the DSS-only group, via regulation of inflammatory mediators and M2 macrophage polarization^[1].
Leucrose (25-50% of total sucrose replaced; p.o.; ad libitum in diet; 12 weeks) improves fasting blood glucose levels, reduces hepatic triglyceride accumulation, downregulates hepatic lipogenesis-related genes, and upregulates hepatic β-oxidation-related genes in obese mice, with the 50% replacement showing greater potency for hepatic triglyceride reduction and β-oxidation gene activation^[2].
Leucrose (25% indiet; p.o.; daily; 6 weeks) supports normal growth in weanling male SPF-Sprague-Dawley rats, with body weight gain, protein efficiency, and energy efficiency statistically equivalent to sucrose or corn starch controls^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 5-week-old, 18-20 g, DSS-induced colitis model)^[1]
Dosage:

25% of total sucrose content replaced with leucrose; 50% of total sucrose content replaced with leucrose
Administration:

p.o.; ad libitum in diet; continuously for 5 weeks
Result:

Attenuated DAI scores at day 19 by 59.2% (25% replacement) and 56.9% (50% replacement) compared to the DSS-only group.
Suppressed DAI area under the curve (AUC) scores by 25.4% (25% replacement) and 37.3% (50% replacement) compared to the DSS-only group.
Restored colon length by 12.6% (25% replacement) and 20.3% (50% replacement) compared to the DSS-only group.
Reduced myeloperoxidase (MPO) activity by 30.4% (25% replacement) and 31.9% (50% replacement) compared to the DSS-only group.
Reduced colon tissue iNOS protein levels by 89.3% (50% replacement) and COX2 protein levels by 84.0% (50% replacement) compared to the DSS-only group.
Down-regulated colon tissue mRNA levels of MCP-1, TNFα, and IL-1β by 44.7%, 34.7%, and 81.1% respectively in the 50% replacement group compared to the DSS-only group.
Reduced plasma IL-1β concentrations by 36.9% (25% replacement) and 34.4% (50% replacement) compared to the DSS-only group.
Significantly reduced colon tissue F4/80-positive macrophage infiltration compared to the DSS-only group in both leucrose groups.
Significantly increased colon tissue mRNA levels of M2 polarization markers Arg1 and Ym1 in both leucrose groups, and CD206 in the 50% replacement group only, compared to the DSS-only group.

Animal Model:

C57BL/6 (5-week-old male, 18-20 g, high-fat diet-induced obesity model)^[2]
Dosage:

25% of total sucrose replaced with leucrose; 50% of total sucrose replaced with leucrose
Administration:

p.o.; ad libitum in diet; 12 weeks
Result:

Reduced fasting blood glucose levels to 141 mg/dL (L25 group) and 133 mg/dL (L50 group), compared to HFD control's 184 mg/dL.
Reduced hepatic triglyceride content to 70 mg/g in L50 group compared to HFD control; L25 group showed non-significant reduction.
Downregulated peroxisome proliferator-activated receptor γ (Pparg) in L25 and L50 groups; downregulated sterol regulatory element binding protein 1C (Srebf1) in both leucrose groups; fatty acid synthase (Fasn) showed non-significant downward trend.
Upregulated peroxisome proliferator-activated receptor α (Ppara) and acyl CoA oxidase (Acox1) in L50 group; upregulated carnitine palmitoyltransferase 1A (Cpt1a) in both L25 and L50 groups, reversing HFD-induced downregulation.

Chemical Information

CAS No. 7158-70-5
Appearance Solid
Molecular Weight 342.30
Formula C₁₂H₂₂O₁₁
Color White to off-white
SMILES

OCC([C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO)=O
Synonyms

5-O-α-D-Glucopyranosyl-D-fructose
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H₂O : 70 mg/mL (204.50 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9214 mL

14.6071 mL

29.2141 mL

5 mM

0.5843 mL

2.9214 mL

5.8428 mL

10 mM

0.2921 mL

1.4607 mL

2.9214 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kim E, et al. Leucrose, a natural sucrose isomer, suppresses dextran sulfate sodium (DSS)-induced colitis in mice by regulating macrophage polarization via JAK1/STAT6 signaling[J]. Journal of Functional Foods, 2020, 74: 104156.

[2]. Lee J, et al. Leucrose, a Sucrose Isomer, Suppresses Hepatic Fat Accumulation by Regulating Hepatic Lipogenesis and Fat Oxidation in High-fat Diet-induced Obese Mice. J Cancer Prev. 2018;23(2):99-106. [Content Brief]

[3]. Ziesenitz S C, et al. Cariological assessment of leucrose [D-glucopyranosyl-α (1→ 5)-D-fructopyranose] as a sugar substitute[J]. Caries Research, 1989, 23(5): 351-357.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	2.9214 mL	14.6071 mL	29.2141 mL	73.0354 mL
	5 mM	0.5843 mL	2.9214 mL	5.8428 mL	14.6071 mL
	10 mM	0.2921 mL	1.4607 mL	2.9214 mL	7.3035 mL
	15 mM	0.1948 mL	0.9738 mL	1.9476 mL	4.8690 mL
	20 mM	0.1461 mL	0.7304 mL	1.4607 mL	3.6518 mL
	25 mM	0.1169 mL	0.5843 mL	1.1686 mL	2.9214 mL
	30 mM	0.0974 mL	0.4869 mL	0.9738 mL	2.4345 mL
	40 mM	0.0730 mL	0.3652 mL	0.7304 mL	1.8259 mL
	50 mM	0.0584 mL	0.2921 mL	0.5843 mL	1.4607 mL
	60 mM	0.0487 mL	0.2435 mL	0.4869 mL	1.2173 mL
	80 mM	0.0365 mL	0.1826 mL	0.3652 mL	0.9129 mL
	100 mM	0.0292 mL	0.1461 mL	0.2921 mL	0.7304 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Leucrose

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Anti-diabetic Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

All JAK Isoforms

All STAT Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Leucrose Related Classifications

Cat. No.: HY-123115